PDL BioPharma (NASDAQ: PDLI) reported Q1 EPS of $0.01, $0.08 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.5 million versus the consensus estimate of $56.9 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.